Consistent with these findings, our study found that PBRM1 deficiency in colorectal cancer enhances immunotherapy response, suggesting that PBRM1 may be an important biomarker and a potential therapeutic target for stratifying patients. The gene discussed is PBRM1; the disease is colorectal cancer.